Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    4,553

Stocks News & Analysis

stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Tesla: Shares fall as deliveries come in below consensus

Long-term growth less reliant on auto sales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.702.000.02%
CAC 408,263.87355.134.49%
DAX 4024,080.631,159.045.06%
Dow JONES (US)47,909.921,325.462.85%
FTSE 10010,608.88260.092.51%
HKSE25,893.02776.493.09%
NASDAQ22,634.99617.142.80%
Nikkei 22556,308.422,878.865.39%
NZX 50 Index13,336.7382.790.62%
S&P 5006,782.81165.962.51%
S&P/ASX 2008,951.8021.00-0.23%
SSE Composite Index3,995.00104.832.69%

Market Movers